Articles from Omniscient Neurotechnology

CHICAGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Omniscient (“o8t®”), a global pioneer in the use of AI to decode the human brain, today announced the issuance of a new Category III Current Procedural Terminology (CPT®) code by the American Medical Association (AMA).

BUFFALO, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Omniscient (o8t®), the global leader in connectomics, is proud to announce a groundbreaking partnership with The Jacobs Institute, Inc. (JI), a one-of-a-kind non-profit medical device innovation center. This collaboration marks the official launch of the Connectomics Innovation Program, a transformative initiative designed to integrate connectomics into clinical research, patient care, and medical education.

SYDNEY, June 11, 2024 (GLOBE NEWSWIRE) -- Omniscient (“o8t®”), pioneering the use of AI to decode the human brain, today announced the conclusion of a successful Series C funding round, bringing total capital raised to US$60 million. This represents the most recent milestone in the company’s history of continued growth, with two FDA-cleared products to date.

SYDNEY, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Omniscient, the world leader in using AI to decode the human brain, today announced FDA clearance of its new functional brain mapping software release, ‘Quicktome FC (Functional Connectome)’, which can reveal in a single scan the unique connectivity patterns of an individual’s brain. Through this major platform upgrade to their award-winning Quicktome platform, which is currently used in neurosurgical applications, the company is expanding the software's use to empower connectomic insights for a wider array of neurological disciplines.

Omniscient Neurotechnology Pty (“o8t™”), a neuroscience company focused on mapping and quantifying the human brain, announced that its Quicktome™ automated brain mapping platform has won the 2022 South By Southwest® (SXSW) Innovation Award, which acknowledges the most exciting tech developments in the connected world. Quicktome was lauded for its innovative ability to harness A.I. and machine learning to create a uniquely powerful view into the brain’s connections.

Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping software company, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Quicktome™, a digital brain mapping platform that allows neurosurgeons to visualize and understand a patient's brain networks prior to performing life-changing brain surgery. This announcement occurs on Glioblastoma Awareness Day, a day dedicated to increasing public understanding of the most common, complex, treatment-resistant, and deadliest type of brain cancer.

Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping technology company, today announced the completion of an AUD 40 million Series B financing round. The funding was led by family offices and high-net worth individuals, including Hancock Prospecting’s Executive Chairman Mrs. Gina Rinehart, and prominent fund manager Will Vicars.